GlassScriptPhysician profile
Thomas S Hamilton
NPI 1346496551
$4,220.73
in general payments reported to CMS, 2019-2025
23 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $662 · 2021: $853 · 2022: $657 · 2023: $730 · 2024: $591 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.24 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $751.45 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $489.72 | 2019-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $456.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $381.08 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $314.56 | 2021-2025 | |
| Amgen INC. | $314.00 | 2019-2024 | Evenity, Prolia, Repatha |
| Pfizer INC. | $312.76 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.63 | 2020-2022 | |
| Abbott Laboratories | $197.37 | 2023-2025 | Freestyle Libre |
| Takeda Pharmaceuticals U.S.A., INC. | $159.88 | 2020-2025 | Trintellix |
| Currax Pharmaceuticals LLC | $137.22 | 2020-2023 | Nexletol, Nexlizet, Contrave |
| Sanofi-Aventis U.S. LLC | $91.10 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $78.40 | 2023-2024 | Quviviq |
| Dexcom, INC. | $62.33 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $58.15 | 2019-2025 | Invega Sustenna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $46.04 | 2020-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $28.24 | 2019 | |
| Allergan, INC. | $24.85 | 2019 | |
| Optinose US, INC. | $18.10 | 2023 | |
| Apria Healthcare LLC | $15.74 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.20 | 2020 | |
| Eisai INC. | $12.18 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.